Core--National Cell Procuremen

核心--全国电池采购商

• 批准号: 7154583
• 负责人: Pamela S Becker
• 金额: $ 49.93万
• 依托单位: UNIVERSITY OF WASHINGTON
• 依托单位国家: 美国
• 财政年份: 2005
• 资助国家: 美国
• 起止时间: 2005-09-29 至 2006-08-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7154583
• 关键词: animal tissue; biomedical facility; cell population study; cooperative study; cord blood; cryopreservation; flow cytometry; hematology; hematopoietic stem cells; human subject; human tissue; postmortem; tissue /cell culture; tissue /cell preparation

The specific aims of the National Hematopoietic Progenitor Cell Processing Core remain similar to those from the previous PEGT grant period, to provide NIH-funded investigators with large numbers of enriched human hematopoietic stem cells or other cell populations to facilitate their basic research and pre-clinical studies. The Core will accomplish this by first procuring sufficient amounts of starting material for large-scale processing and cell selection. The Core operates a donor recruitment program to obtain G-CSF mobilized and non-mobilized collections from normal volunteers, and also obtains cadaveric bone marrow from the Northwest Tissue Center and National Disease Research Interchange. The Core processes these collections to obtain large numbers of enriched cell subsets, the types of selections offered include CD34, CD14, CD19, CD22, CDS, CD4, or CDS. The Core characterizes these cells by 3 or 4-color flow cytometry, cryopreserves aliquots for long-term storage, and ships components to requesting investigators. During the previous PEGT the Core performed over 80 large-scale enrichments for CD34, with average final purities >90% and yields of 60%. Additional selections for CD14 (n=40) and T-cells (n=20) have also been performed, with even higher final purities and yields. The Core has distributed over 3,500 vials of enriched cells to more than 60 different investigators from more than 30 institutions, at a greatly reduced cost relative to commercial suppliers. In summary, this Core will continue to provide a unique and critical service in support of NIH funded research, supplying investigators with large numbers of enriched cell populations for in vitro experimentation, animal model testing, and pre-clinical evaluations.

国家造血祖细胞加工核心的具体目的与上一个PEGT赠款期的核心相似，以向NIH资助的研究人员提供大量富集的人类造血干细胞或其他细胞群体，以促进其基础研究和临床前研究。核心将通过首先采购足够数量的大规模处理和细胞选择的起始材料来实现这一目标。核心运营一项供体招聘计划，以从正常志愿者那里获取G-CSF的动员和非动物的收集，还从西北组织中心和国家疾病研究的交换中获得了尸体骨髓。核心过程这些集合以获得大量富集的单元子集，所提供的选择类型包括CD34， CD14，CD19，CD22，CDS，CD4或CDS。核心通过3或4色流式细胞术，冷冻保存的等分试样以及请求研究人员的船只组件来表征这些细胞。在上一个PEGT期间，核心对CD34进行了80多种大规模富集，平均最终纯度> 90％，单产为60％。还执行了CD14（n = 40）和T细胞（n = 20）的其他选择，最终纯度和收率更高。该核心已将超过3500瓶的富集细胞分布给了来自30多个机构的60多个不同的研究人员，相对于商业供应商，成本大大降低。总而言之，该核心将继续为支持NIH资助的研究提供独特而关键的服务，为研究人员提供大量富集的细胞种群 体外实验，动物模型测试和临床前评估。